Chembio Diagnostics Announces US Distribution Agreement to Expand Reach of DPP COVID-19 Serological Test with Thermo Fisher S...
May 18 2020 - 07:00AM
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading
point-of-care diagnostic company focused on infectious diseases,
today announced it has signed a multi-year, non‑exclusive agreement
with Thermo Fisher Scientific’s healthcare channel, to
distribute Chembio’s DPP COVID-19 System in the United
States. The DPP COVID‑19 System is a rapid serological test and
analyzer that provides numerical readings for both IgM and IgG
antibody levels within 15 minutes from a finger stick drop of
blood. The DPP COVID‑19 System can include either Chembio’s Micro
Reader 1 or Micro Reader 2 analyzer.
“We are pleased to announce our strategic supplier
partnership with the Fisher Healthcare channel, which will
significantly increase our commercial footprint by providing access
to thousands of hospital and physician office moderately complex
labs across the country,” stated Rick Eberly, Chembio’s President
and Chief Executive Officer. “We have initiated a comprehensive
training and marketing program for the Fisher Healthcare channel
sales team, in order to expand the targeted coverage for this
important segment of the market as soon as possible.”
To learn more about this product and how to
purchase, please visit www.fisherhealthcare.com.
About Chembio DiagnosticsChembio
is a leading point-of-care diagnostics company focused on detecting
and diagnosing infectious diseases, including COVID-19, sexually
transmitted disease, and fever and tropical disease. The company’s
patented DPP technology platform, which uses a small drop of blood
from the fingertip, provides high-quality, cost-effective results
in approximately 15 minutes. Coupled with Chembio’s extensive
scientific expertise, its novel DPP technology offers broad market
applications beyond infectious disease. Chembio’s products are sold
globally, directly and through distributors, to hospitals and
clinics, physician offices, clinical laboratories, public health
organizations, government agencies, and consumers. Learn more at
www.chembio.com.
DPP is Chembio’s registered trademark. For convenience, this
trademark appears in this release without ® symbols, but that
practice does not mean that Chembio will not assert, to the fullest
extent under applicable law, its rights to the trademark.
Contact: Philip TaylorGilmartin
Group(415) 937-5406investor@chembio.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Mar 2023 to Mar 2024